Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Kidney and Blood Pressure Research · 2023
DOI: 10.1159/000533834 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney and Blood Pressure Research, 2023. Verfasst von Yasufumi Seki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan, seki.yasufumi@twmu.ac.jp. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypertension. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity.
Methods
In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment.
Results
Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008).
Conclusion
Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan, seki.yasufumi@twmu.ac.jp.
- Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Zitieren
APA
Seki, Y., Morimoto, S., Kimura, S., Takano, N., Yamashita, K., Bokuda, K., Sasaki, N., Watanabe, D., & Ichihara, A. (2023). Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research. https://doi.org/10.1159/000533834
Vancouver
Seki Y, Morimoto S, Kimura S, Takano N, Yamashita K, Bokuda K, et al. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research. 2023. doi:10.1159/000533834
BibTeX
@article{Seki2023,
author = {Seki, Yasufumi and Morimoto, Satoshi and Kimura, Shihori and Takano, Noriyoshi and Yamashita, Kaoru and Bokuda, Kanako and Sasaki, Nobukazu and Watanabe, Daisuke and Ichihara, Atsuhiro},
title = {Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus},
journal = {Kidney and Blood Pressure Research},
year = {2023},
doi = {10.1159/000533834}
}
EUVIMED